Interaction of Bcl-Abl Oncoprotein with the Glg1 Protein in K562 Cells: Its Role in the Pathogenesis of Chronic Myeloid Leukemia
Abstract
Abstract Chronic Myeloid Leukemia (CML) is a clonal myeloproliferative disease characterized by the occurrence of the Bcr-Abl fusion oncoprotein, which resulted from a reciprocal translocation between chromosomes 9 and 22. The Golgi complex-localized protein 1(GLG1) was identified by mass spectrometry as a potential interaction partner to the pleckstrin homology (PH) domain of the Bcr-Abl oncoprotein. The GLG1 protein is a transmembrane protein known also as MG-160, ESL-1, and CFR-1. Irregularities in the GLG1 functions affect the adhesion, mobility, and migration of cells. In this study, the interaction between the GLG1 protein and the Bcr-Abl oncoprotein is shown for the first time. With imunofluorescence and confocal microscopy, colocalization of the GLG1protein and the Bcr-Abl oncoprotein to the Golgi complex has been detected. A GLG1 protein form phosphorylated at the tyrosine site in K562 cells has also been detected, and Tyr phosphorylation sites for GLG1 isoforms were predicted. The authors believe that the oncoprotein phosphorylates the GLG1 protein, at the cost of its Abl part, during the GLG1–Bcr-Abl protein interaction in the Golgi complex, thus affecting its activity and disrupting the descending signaling pathways that may be crucial for the development and progression of the disease.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Variations in genes related to oxidative stress, such as CAT-262 C>T, GPX1 Pro198Leu, and GSTP1 Ile105Val, influence the risk of developing BCR-ABL negative myeloproliferative neoplasms.
“Additionally, variations in genes related to oxidative stress, such as CAT-262 C>T, GPX1 Pro198Leu, and GSTP1 Ile105Val, influence the risk of developing BCR-ABL negative myeloproliferative neoplasms [18,19,20].”
From Comprehensive review of chronic stress pathways and the efficacy of behavioral stress reduction programs (BSRPs) in managing diseases. (2024) · cites this paper as [18]
The stress response gene SIRT1, activated by BCR-ABL, promotes leukemogenesis by enhancing CML cell survival and proliferation.
“The stress response gene SIRT1, activated by BCR-ABL, promotes leukemogenesis by enhancing chronic myeloid leukemia (CML) cell survival and proliferation.”
From Comprehensive review of chronic stress pathways and the efficacy of behavioral stress reduction programs (BSRPs) in managing diseases. (2024) · cites this paper as [18]
SIRT1 activation involves deacetylation of multiple substrates, including FOXO1, p53, and Ku70.
“SIRT1 activation involves the deacetylation of multiple substrates, including FOXO1, p53, and Ku70.”
From Comprehensive review of chronic stress pathways and the efficacy of behavioral stress reduction programs (BSRPs) in managing diseases. (2024) · cites this paper as [18]
Cites
A practical guide to evaluating colocalization in biological microscopy.
Dunn, K., Kamocka, M., & McDonald, J. (2011) · American Journal of Physiology - Cell Physiology · doi:10.1152/ajpcell.00462.2010 · Cited by 1,998 · see citing works
Molecular biology of bcr-abl1–positive chronic myeloid leukemia
Quintás‐Cardama, A., & Cortes, J. E. (2008) · Blood · doi:10.1182/blood-2008-03-144790 · Cited by 744 · see citing works
Zarbock, A., Ley, K. F., McEver, R. P., & Hidalgo, A. (2011) · Blood · doi:10.1182/blood-2011-07-343566 · Cited by 479 · see citing works
Zinchuk, V. S., Zinchuk, O., & Okada, T. (2007) · ACTA HISTOCHEMICA ET CYTOCHEMICA · doi:10.1267/ahc.07002 · Cited by 426 · see citing works
ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity
Colicelli, J. (2010) · Science Signaling · doi:10.1126/scisignal.3139re6 · Cited by 365 · see citing works
The E-selectin-ligand ESL-1 is a variant of a receptor for fibroblast growth factor
Steegmaler, M., Levinovitz, A., Isenmann, S., Borges, E., Lenter, M., Kocher, H. P., Kleuser, B., & Vestweber, D. (1995) · Nature · doi:10.1038/373615a0 · Cited by 351 · see citing works
Statistical tests for measures of colocalization in biological microscopy
McDonald, J. H., & Dunn, K. W. (2013) · Journal of Microscopy · doi:10.1111/jmi.12093 · Cited by 144 · see citing works
Croul, S. E., Mezitis, S. G. E., Stieber, A., et al. (1990) · Journal of Histochemistry & Cytochemistry · doi:10.1177/38.7.2355176 · Cited by 86 · see citing works
IIIDB: a database for isoform-isoform interactions and isoform network modules
Tseng, Y., Li, W., Chen, C., Zhang, S., Chen, J. J. W., Zhou, X. J., & Liu, C.-C. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s2-s10 · Cited by 80 · see citing works
The E-selectin-ligand ESL-1 is located in the Golgi as well as on microvilli on the cell surface
Steegmaier, M., Borges, E., Berger, J., Schwarz, H., & Vestweber, D. (1997) · Journal of Cell Science · doi:10.1242/jcs.110.6.687 · Cited by 78 · see citing works
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities
Flis, S., & Chojnacki, T. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s191303 · Cited by 74 · see citing works
After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies
Wadleigh, M., DeAngelo, D. J., Griffin, J. D., & Stone, R. M. (2004) · Blood · doi:10.1182/blood-2003-11-3896 · Cited by 65 · see citing works
E-selectin ligand-1 controls circulating prostate cancer cell rolling/adhesion and metastasis
Yasmin‐Karim, S., King, M. R., Messing, E. M., & Lee, Y. (2014) · Oncotarget · doi:10.18632/oncotarget.2503 · Cited by 42 · see citing works
Mourelatos, Z., Gonatas, J., Cinato, E., & Gonatas, N. (1996) · DNA and Cell Biology · doi:10.1089/dna.1996.15.1121 · Cited by 38 · see citing works
Re-evaluating the role of BCR/ABL in chronic myelogenous leukemia
Ross, T. S., & Mgbemena, V. E. (2014) · Molecular & Cellular Oncology · doi:10.4161/23723548.2014.963450 · Cited by 37 · see citing works
Miroshnychenko, D., Dubrovska, A., Малюта, С. С., et al. (2009) · Experimental Cell Research · doi:10.1016/j.yexcr.2009.11.014 · Cited by 33 · see citing works
Salem, A., Loghavi, S., Tang, G., Huh, Y. O., Jabbour, E. J., Kantarjian, H. M., Wang, W., Hu, S., Luthra, R., Medeiros, L. J., et al. (2017) · American Journal of Hematology · doi:10.1002/ajh.24710 · Cited by 30 · see citing works
Ahn, J., Febbraio, M., & Silverstein, R. L. (2005) · Journal of Cell Science · doi:10.1242/jcs.02310 · Cited by 23 · see citing works
Current perspectives for the treatment of chronic myeloid leukemia
Aladağ, E., & Haznedaroğlu, İ. C. (2019) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1810-81 · Cited by 20 · see citing works
Järås, M., Johnels, P., Ågerstam, H., Lassen, C., Rissler, M., Edén, P., Cammenga, J., Olofsson, T., Bjerrum, O. W., Richter, J., et al. (2009) · Experimental Hematology · doi:10.1016/j.exphem.2008.11.003 · Cited by 11 · see citing works
Immunocytochemical study of Bcr and Bcr-Abl localization in K562 cells.
Telegeev, G. D., Dubrovska, A. N., Nadgorna, V. A., et al. (2010) · PubMed · Cited by 9 · see citing works
Self-citationGurianov, D. S., Antonenko, S. V., & Телегеев, Г. Д. (2016) · Biopolymers and Cell · doi:10.7124/bc.000909 · Cited by 9 · see citing works
Self-citationMiyaoka, Y., Kato, H., Ebato, K., et al. (2011) · Biochemical Journal · doi:10.1042/bj20110318 · Cited by 6 · see citing works
Abstract 3245: The Golgi protein GLG1 participates in tumor progression
Planche, A., Bacac, M., & Stamenkovic, I. (2012) · Cancer Research · doi:10.1158/1538-7445.am2012-3245 · Cited by 3 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Shchaslyvyi, A. Y., Antonenko, S. V., & Telegeev, G. D. (2024) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph21081077 · Cited by 73 · see citing works
Self-citation
- Authors
- Antonenko, S. V., Kravchuk, I. V., & Telegeev, G. D.
- Affiliations
- National Academy of Sciences of Ukraine (UA)
- Corresponding author
- Antonenko, S. V.
- ORCID
- Kravchuk, I. V.
- Venue
- Cytology and Genetics
- Publisher
- Allerton Press
- Published
- 2020-01
- Volume
- 54
- Issue
- 1
- Pages
- 48-54
- ISSN
- 0095-4527 (ISSN-L)
- 1934-9440
- OpenAlex
- W3006479645
- Cited by
- 10
- References
- 24
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 1 · 2023: 3 · 2021: 1
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- Locations
- Cytology and Genetics (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- Bcr-Abl oncoprotein, Golgi apparatus, protein-protein interaction, tyrosine phosphorylation, K562 cells, chronic myeloid leukemia, pleckstrin homology domain, signaling pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
